Search

Search Constraints

You searched for: Author/Creator Brody, Mark

Search Results

1. P2‐009: CLINICAL TESTING OF LONGEVERON MESENCHYMAL STEM CELLS (LMSCS) TO TREAT ALZHEIMER'S DISEASE. (1st July 2006)

2. IC‐P‐108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. (1st July 2014)

3. P2‐039: PROGRESS OF THE PHASE I CLINICAL TRIAL TO EVALUATE LONGEVERON ALLOGENEIC MESENCHYMAL STEM CELLS (LMSCS) AS A POTENTIAL THERAPEUTIC FOR ALZHEIMER'S DISEASE. (1st July 2019)

4. P1–343: A phase II study of the gamma‐secretase inhibitor avagacestat (BMS‐708163) in predementia Alzheimer's disease. (1st July 2013)

5. Clinical evaluation of allogeneic mesenchymal stem cells for Alzheimer's disease: Human/Human trials: Inflammation. (7th December 2020)

6. The Effects of Multiple Doses of Lomecel‐B, Longeveron' s Cell‐based Therapy, on Alzheimer's disease: Study Design and Rationale of this Phase 2a Multi‐ center Clinical trial. (20th December 2022)

7. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Issue 7 (July 2021)

8. P2‐202: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. (1st July 2014)

9. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. (22nd May 2018)

10. Safety and efficacy of Lomecel‐B in patients with mild Alzheimer's disease: Results of a double‐blinded, randomized, placebo‐controlled phase 1 clinical trial. (31st December 2021)